| Old Articles: <Older 9011-9020 Newer> |
|---|
 |
Chemistry World
January 13, 2015
Rebecca Trager |
Ansun settles fraud case for $2m Ansun Biopharma has agreed to pay $2 million to settle a criminal and civil case for submitting false and fraudulent claims against grants and a contract with the US National Institutes of Health.   |
Chemistry World
January 12, 2015
Phillip Broadwith |
Biogen Idec to buy Convergence for pain pipeline The deal gives Biogen Idec access to a promising candidate for neuropathic pain, but also significant R&D expertise in pain and neurology. |
Chemistry World
January 9, 2015
Rebecca Trager |
US poised to approve its first 'biosimilar' drug A key committee of the US Food and Drug Administration has voted in favor of licensing a copycat version of a biological drug. If approved, Sandoz's Zarxio (filgrastim) would be the first 'biosimilar' drug available in the US. |
Fast Company
February 2015
Jon Gertner |
What's Lurking In Your Microbiome? Possibly, a Cure for Disease Second Genome is a small company that focuses on the microbiome: the trillions of bacteria, viruses, and fungi that people carry around with them from birth until death. |
Chemistry World
January 7, 2015
Rebecca Trager |
Myriad loses appeal on cancer gene test patents Myriad Genetics has lost its appeal over patents on the BRCA genes that are associated with a higher risk of breast and ovarian cancer. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
Chemistry World
December 24, 2014
Phillip Broadwith |
EU recommends Parkinson's drug for approval The first new drug in 10 years for Parkinson's disease has been recommended for approval by the European Committee for Medicinal Products for Human Use. |
Chemistry World
December 16, 2014
Anthony King |
Antimicrobial resistance will kill 300 million by 2050 without action A new report looks to a future where drug resistance is not tackled between now and 2050. |
Chemistry World
December 11, 2014 |
Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin). |
Chemistry World
December 10, 2014 |
Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council. |
| <Older 9011-9020 Newer> Return to current articles. |
